✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals

Parmax Pharma Ltd.

PARMAX

Market Cap
₹18 Cr.
P/E
0.00

Parmax Pharma Ltd.

  • Parmax Pharma
  • Emmessar Biotech&Nut
  • Norris Medicines
FAQs on Parmax Pharma Ltd. Shareprice

Parmax Pharma has given better returns compared to its competitors.
Parmax Pharma has grown at ~49.57% over the last 1yrs while peers have grown at a median rate of 20.0%

Parmax Pharma is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Parmax Pharma is 0.0, while 3 year average PE is 28.67.
Also latest EV/EBITDA of Parmax Pharma is 1133 while 3yr average is 43.65.

View FAQ's On Business
Growth Table
  • Parmax Pharma Ltd.
  • Emmessar Biotech&Nut
  • Norris Medicines
Balance Sheet
  • Parmax Pharma Ltd.
  • Emmessar Biotech&Nut
  • Norris Medicines
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Parmax Pharma Ltd.
  • Emmessar Biotech&Nut
  • Norris Medicines
Cash Flow
  • Parmax Pharma Ltd.
  • Emmessar Biotech&Nut
  • Norris Medicines
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Parmax Pharma Ltd.
  • Emmessar Biotech&Nut
  • Norris Medicines
Quarterly Results
  • Parmax Pharma Ltd.
  • Emmessar Biotech&Nut
  • Norris Medicines
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Parmax Pharma Ltd. Financials

Parmax Pharma balance sheet is weak and might have solvency issues

The net debt of Parmax Pharma is decreasing.
Latest net debt of Parmax Pharma is ₹5.67 Crs as of Sep-24.
This is less than Mar-24 when it was ₹5.81 Crs.

The profit is oscillating.
The profit of Parmax Pharma is -₹2.05 Crs for TTM, -₹5.78 Crs for Mar 2024 and -₹0.1 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Parmax Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech